AUSTRALIAN pharmaceutical firm Phebra has announced a $4million expansion of its Sydney multi-purpose sterile injectables site, to be in production by Jun.
The footprint of the current Phebra facilty will increase by over 3,000m with the company taking-over the remainder of its building in Lane Cove West following the expiration of the tenant's lease.
Phebra Chief Executive Officer, Dr Mal Eutick, said the expansion would boost the company's current space, warehousing, packaging and support services for its pipeline of critical medicines, as well as catering to meet the needs of export markets.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Feb 19
